Abratt R P, Pontin A R, Ball H S
Department of Radiotherapy, Groote Schuur Hospital, Observatory South Africa.
Cancer Immunol Immunother. 1993 Jul;37(2):140-1. doi: 10.1007/BF01517047.
Twelve patients with metastatic renal cell carcinoma were entered into a phase-2 study of an 8-week course of interferon (INF) therapy. INF was given subcutaneously at a dose of 3 mu, three times per week. The patients were WHO performance status 0-2. A complete response was obtained in two patients (17% response rate), which has been maintained at 23 and 45 months. One of these patients presented with cranial and lung metastases and received cranial irradiation and decradron concurrent with INF. The toxicity of INF has been low. The optimal duration of INF therapy warrants further evaluation.
12例转移性肾细胞癌患者进入了一项为期8周的干扰素（INF）治疗的2期研究。INF以3百万单位的剂量皮下注射，每周3次。患者的世界卫生组织（WHO）体能状态为0 - 2级。2例患者获得完全缓解（缓解率为17%），缓解状态分别维持了23个月和45个月。其中1例患者有颅骨和肺部转移，在接受INF治疗的同时还接受了头颅放疗和地塞米松治疗。INF的毒性较低。INF治疗的最佳持续时间有待进一步评估。
